Atrovastatin API Market

1
Atrovastatin API Market 2020-2023
Industry Survey, Growth, Competitive
Landscapeand Forecasts to 2023
2
Atrovastatin API Market 2020-2023
Atrovastatin API Market Highlights
The Global Atorvastatin API Market is estimated
to be valued at USD 4,25,804.16 thousand by
2023 and is expected to register a CAGR of
3.34 during the forecast period. The
hypercholesterolemia segment is expected to lead
the market and register a substantial CAGR to
reach USD 2,10,753.23 thousand by the end of
2023. High prevalence of hypercholesterolemia is
expected to drive the market growth.
Additionally, the segment is projected to exhibit
the highest CAGR of 4.09 from 2018 to
2023. North America accounted for the largest
market share of 40.64 in 2017, and the regional
market is projected to register a CAGR of
3.10 during the forecast period. Asia-Pacific is
expected to register the fastest CAGR. The
Chinese market is projected to exhibit the
highest growth rate of 5.86 during the forecast
period from 2018 to 2023.

3
Atrovastatin API Market 2020-2023
Atrovastatin API Market Regional Analysis
North America accounted for the largest market
share of 40.64 in 2017, and the regional market
is projected to register a CAGR of 3.10 during
the forecast period. Asia-Pacific is expected to
register the fastest CAGR. The Chinese market is
projected to exhibit the highest growth rate
of 5.86 during the forecast period from 2018 to
2023.  The European market is estimated to
exceed USD 1,31,094.04 thousand by 2023. High
prevalence of hypercholesterolemia and mixed
dyslipidemia are driving the growth of the
Atorvastatin API market in the region. France is
the major contributor to the growth of the
regional market, followed by the
UK. Browse Complete Report with TOC _at_ https//www
.marketresearchfuture.com/reports/atorvastatin-api
-market-7885
4
Atrovastatin API Market 2020-2023
Atrovastatin API Market Segmental Analysis

• The hypercholesterolemia segment is expected to
  lead the market and register a substantial CAGR
  to reach USD 2,10,753.23 thousand by the end
  of 2023. High prevalence of hypercholesterolemia
  is expected to drive the market growth.
  Additionally, the segment is projected to exhibit
  the highest CAGR of 4.09 from 2018 to 2023.
• Global Atorvastatin API Market, by Application
• Hypercholesterolemia
• Hypertriglyceridemia
• Dyslipidemia
• Others

5
Atrovastatin API Market 2020-2023
Atrovastatin API Market Key Players

•  Teva Pharmaceutical Industries Ltd (Israel)
• Jubilant Life Sciences Ltd (India)
• Dr. Reddys Laboratories Ltd (India)
• Sun Pharmaceutical Industries Ltd (India)
• Ind-Swift Labs Ltd (India)
• Morepen Laboratories Ltd (India)
• Zhejiang Hisun Pharmaceutical Co Ltd (China)
• Anuh Pharma Ltd (India)
• Centrient Pharmaceuticals (The Netherlands)
• Cadila Pharmaceuticals (India) 
• Avail Free Sample _at_ https//www.marketresearchfutu
  re.com/sample_request/7885

6
ABOUT US
MARKET RESEARCH FUTURE At Market Research Future
(MRFR), we enable our customers to unravel the
complexity of various industries through our
Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports
(3R), Continuous-Feed Research (CFR), and Market
Research Consulting Services. MRFR team have
supreme objective to provide the optimum quality
market research and intelligence services to our
clients. Our market research studies by products,
services, technologies, applications, end users,
and market players for global, regional, and
country level market segments, enable our clients
to see more, know more, and do more, which help
to answer all their most important questions. In
order to stay updated with technology and work
process of the industry, MRFR often plans
conducts meet with the industry experts and
industrial visits for its research analyst
members. For more information kindly visit
www.marketresearchfuture.com or contact us at
info_at_marketresearchfuture.com Copyright 2018
Market Research Future All Rights Reserved. This
document contains highly confidential information
and is the sole property of Market Research
Future. No part of it may be circulated, copied,
quoted, or otherwise reproduced without the
written approval of Market Research Future.
7
(No Transcript)